Filling the need for trusted information on national health issues…

Trending on kff Open Enrollment Medicare Part D Medicaid Expansion

Kaiser Daily Global Health Policy ReportPrivate Sector Involvement Search Results « » The Henry J. Kaiser Family Foundation

Private Sector Involvement

  • your selections
Clear Search

Filter Results



  • results
Long-Acting Injectable HIV Treatment Shows Promise In Clinical Trials

Associated Press: J&J, ViiV: 2 injections every month or 2 could control HIV “Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two. Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, on…

Opinion Pieces Discuss Issues Surrounding Ebola Response

The Lancet: Ebola: burying the bodies David L. Heymann, head and senior fellow at the Chatham House Center on Global Health Security and professor of infectious disease epidemiology at the London School of Hygiene & Tropical Medicine “…The difficult and heroic work of [burial teams in West Africa] might have…

Guardian Live Chat Outlines 3 Key Lessons For Private Sector’s Role In SDGs

The Guardian: Three things we learned about how business can help achieve SDGs “…Focused on tackling poverty, education, health, hunger ,and environmental issues around the world, the private sector has been involved in devising the framework for the SDGs. In a recent live chat we learned three key lessons about…

Malaria Parasite Genotype Contained In Experimental Vaccine Could Impact Efficacy, Study Shows

News outlets report on a study published in the New England Journal of Medicine examining the relationship between an experimental malaria vaccine’s efficacy and the parasite genotypes it uses. Nature: Parasite mismatch explains mediocre performance of leading malaria vaccine “A malaria vaccine that has disappointed in clinical trials stumbled in…

Disagreement Over TPP’s Pharmaceutical Provision Could Derail Agreement, The Hill Reports

The Hill: Pharma flap imperils president’s trade deal “…The exact details of the pharmaceutical provision [contained in the Trans-Pacific Partnership], which involves a class of drugs called biologics, won’t be made public until later this month. Still, it’s already threatening to drag out — and possibly derail — the approval…